{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:18:06Z","timestamp":1787807886350,"version":"build-2784847793"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Contrast-induced acute kidney injury (CI-AKI) is a frequent complication of coronary angiography and percutaneous coronary intervention (PCI), particularly in patients with type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may exert renoprotective effects, but evidence in the setting of contrast exposure remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between GLP-1 RA therapy and CI-AKI in patients with T2DM undergoing coronary angiography or PCI for acute coronary syndromes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 336 patients with T2DM who underwent coronary angiography or PCI between May 2023 and March 2025. Patients receiving stable GLP-1 RA therapy (n=149) were compared with non-users (n=187). Serum creatinine and estimated glomerular filtration rate (eGFR) were measured at baseline and 48\u201372 hours after the procedure. CI-AKI was defined as a serum creatinine increase of \u22650.5 mg\/dL or \u226525% from baseline within 72 hours. Multivariable logistic regression was used to identify independent predictors of CI-AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CI-AKI occurred less frequently among GLP-1 RA users than non-users (8.7% vs 25.7%, p&amp;lt;0.001). At 48\u201372 hours, eGFR was higher in the GLP-1 RA group (67.1\u00a0\u00b1\u00a012.1 vs 58.0\u00a0\u00b1\u00a011.8 mL\/min\/1.73 m\u00b2, p&amp;lt;0.001), whereas serum creatinine did not differ significantly (1.02\u00a0\u00b1\u00a00.73 vs 1.17\u00a0\u00b1\u00a01.57 mg\/dL, p=0.084). GLP-1 RA use was independently associated with lower odds of CI-AKI (OR 0.290, 95% CI 0.119\u20130.708; p=0.007). Increasing age (OR 1.332, 95% CI 1.214\u20131.462; p&amp;lt;0.001) and ST-segment elevation myocardial infarction (OR 5.039, 95% CI 2.368\u201310.722; p&amp;lt;0.001) were associated with higher odds, whereas higher baseline eGFR was associated with lower odds (OR 0.919, 95% CI 0.862\u20130.979; p=0.009).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 RA therapy was independently associated with a lower risk of CI-AKI in patients with T2DM undergoing contrast-based coronary procedures. These findings suggest a potential renoprotective association but require confirmation in prospective multicenter studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1930088","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:25:57Z","timestamp":1787804757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventions"],"prefix":"10.3389","volume":"17","author":[{"given":"Dogac","family":"Oksen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Altinbas University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Aslan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Siirt University","place":["Siirt, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Siirt University","place":["Siirt, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagdas","family":"Kaynak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Siirt University","place":["Siirt, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Serin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sisli Etfal Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1180861","article-title":"Prevention of contrast-associated acute kidney injury in an era of increasingly complex interventional procedures","volume":"10","author":"Somkereki","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-024-03570-6","article-title":"Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment","volume":"25","author":"Li","year":"2024","journal-title":"BMC Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595090","article-title":"Contrast-induced nephropathy: a clinical and evidence-based approach","volume":"113","author":"Tepel","year":"2006","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000368","article-title":"Contrast-induced nephropathy: definition, epidemiology, and patients at risk","volume":"100","author":"Mehran","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2024.3980","article-title":"Do sodium-glucose cotransporter 2 inhibitors decrease the risk of contrast-associated acute kidney injury in patients with type II diabetes mellitus","volume":"28","author":"\u00c7abuk","year":"2024","journal-title":"Anatol J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11154-010-9134-4","article-title":"Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications","volume":"11","author":"Tabit","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.03.019","article-title":"Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives","volume":"184","author":"Bhatti","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00967","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms","volume":"11","author":"Kawanami","year":"2020","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2337\/cd19-0100","article-title":"Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance","volume":"38","author":"Almandoz","year":"2020","journal-title":"Clin Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247732","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic kidney disease: from bench to bed-side","volume":"13","author":"Abdelrahman","year":"2024","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s40001-024-02214-7","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: a propensity-matched study","volume":"29","author":"Yang","year":"2024","journal-title":"Eur J Med Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.48176\/esmj.2026.250","article-title":"Association between admission mean arterial pressure and the development of contrast-associated nephropathy within the first 72 hours in patients with NSTEMI","volume":"7","author":"Bulu","year":"2026","journal-title":"Eskisehir Med J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/00033197221116203","article-title":"Prognostic nutritional index predicts contrast-induced nephropathy in patients with acute coronary syndrome","volume":"74","author":"Yuksel","year":"2023","journal-title":"Angiology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.043","article-title":"Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction","volume":"44","author":"Marenzi","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1930088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:25:57Z","timestamp":1787804757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1930088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":27,"alternative-id":["10.3389\/fendo.2026.1930088"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1930088","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1930088"}}